Napo sues Salix for $150M+ in anti-diarrheal contract dispute
This article was originally published in Scrip
Executive Summary
Salix Pharmaceuticals' failure to put the proper manufacturing and commercialization mechanisms in place in advance of US marketing of crofelemer, an investigational anti-diarrheal drug, will cause HIV patients to wait longer for a much-needed treatment once the medicine gains US FDA approval, Napo Pharmaceuticals asserted in a complaint filed last week seeking damages in excess of $150 million.